Research and Markets: Sanofi-Aventis: PharmaVitae Profile 2011 Benchmarks Sanofi-Aventis's performance against key rivals

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/ca4091/sanofiaventis_ph) has announced the addition of the "Sanofi-Aventis: PharmaVitae Profile" report to their offering.

This analysis examines the historical and forecast performance for Sanofi-Aventis in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Gain insight into Sanofi-Aventis's strategic outlook across the next 6 years. Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source. Strategic insight into the prospects for Sanofi-Aventis over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales. Benchmark Sanofi-Aventis's performance against key rivals in the prescription pharmaceutical sector. Analyse the positioning of the company as a diversified healthcare player with an enhanced focus on the vaccine, generic and consumer markets. Assess how the genericization of blockbusters Plavix, Eloxatine, Taxotere, Stilnox/Ambien and Lovenox is expected to significantly impact growth.

Key Topics Covered:

  • Executive Summary
  • SWOT analysis
  • ABOUT THIS PROFILE
  • QUARTERLY UPDATE
  • COMPANY INTRODUCTION
  • COMPANY SALES
  • COMPANY FINANCIALS
  • KEY PRODUCTS
  • APPENDIX

Companies Mentioned:

  • ACS Motion Control Ltd
  • AstraZeneca PLC
  • Automatic Data Processing, Inc.
  • Bristol-Myers Squibb Company
  • Cambridge Antibody Technology Group
  • CDC SPA
  • Citizen Electronics Company Limited
  • Eli Lilly and Company
  • EMI Group PLC
  • GlaxoSmithKline Plc
  • IMS Health
  • Insight Communications Company, Inc.
  • Mayne Pharma
  • Medicines Company, The
  • Merck & Co., Inc.
  • NICE Systems Ltd
  • Novartis AG
  • Novo Nordisk A/S
  • Oxford BioMedica Plc
  • Pfizer Inc
  • Regeneron Pharmaceuticals, Inc.
  • Safety Insurance Group, Inc.
  • Sanofi-Aventis
  • Sepracor Inc.

For more information visit http://www.researchandmarkets.com/research/ca4091/sanofiaventis_ph.

Source: Datamonitor



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   Europe  France

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Medical Supplies

MEDIA:

Logo
 Logo

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.